Boni E Elewski1, Lluís Puig2, Margaret Mordin3, Isabelle Gilloteau4, Bintu Sherif5, Todd Fox4, Ari Gnanasakthy5, Charis Papavassilis4, Bruce E Strober6,7. 1. a University of Alabama at Birmingham , Birmingham , AL , USA. 2. b Department of Dermatology , Hospital de la Sanat Creu i Sant Pau , Barcelona , Spain. 3. c RTI Health Solutions , Ann Arbor , MI , USA. 4. d Novartis Pharma AG , Basel , Switzerland. 5. e RTI Health Solutions , Research Triangle Park , NC , USA. 6. f University of Connecticut Health Center , Farmington , CT , USA. 7. g Probity Medical Research , Waterloo , Canada.
Abstract
BACKGROUND: The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL). OBJECTIVE: To evaluate the association of greater response in skin clearance with improvements in skin-related QOL up to 52 weeks. METHODS: Subjects achieving various levels of skin clearance (PASI 90-100 or PASI 75-89) and Dermatology Life Quality Index (DLQI) (0/1) response were compared using ERASURE and FIXTURE trial data. Similar analyses with IGA ratings of Clear or Almost Clear were performed. RESULTS: Significantly more PASI 90-100 responders at week 12 had DLQI 0/1 response than PASI 75-89 (69.4% vs. 47.1%; p < .001) and sustained DLQI 0/1 response at week 52 (74.0% vs. 56.7%; p < .001). IGA results were similar. CONCLUSIONS: These results show that PASI 90-100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75-89 when considering patients' QOL.
RCT Entities:
BACKGROUND: The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL). OBJECTIVE: To evaluate the association of greater response in skin clearance with improvements in skin-related QOL up to 52 weeks. METHODS: Subjects achieving various levels of skin clearance (PASI 90-100 or PASI 75-89) and Dermatology Life Quality Index (DLQI) (0/1) response were compared using ERASURE and FIXTURE trial data. Similar analyses with IGA ratings of Clear or Almost Clear were performed. RESULTS: Significantly more PASI 90-100 responders at week 12 had DLQI 0/1 response than PASI 75-89 (69.4% vs. 47.1%; p < .001) and sustained DLQI 0/1 response at week 52 (74.0% vs. 56.7%; p < .001). IGA results were similar. CONCLUSIONS: These results show that PASI 90-100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75-89 when considering patients' QOL.
Authors: S K Mahil; N Wilson; N Dand; N J Reynolds; C E M Griffiths; R Emsley; A Marsden; I Evans; R B Warren; D Stocken; J N Barker; A D Burden; C H Smith Journal: Br J Dermatol Date: 2019-09-10 Impact factor: 9.302
Authors: Laura M Sawyer; Kinga Malottki; Celia Sabry-Grant; Najeeda Yasmeen; Emily Wright; Anne Sohrt; Emma Borg; Richard B Warren Journal: PLoS One Date: 2019-08-14 Impact factor: 3.240
Authors: A Blauvelt; H Sofen; K Papp; M Gooderham; S Tyring; Y Zhao; S Lowry; A Mendelsohn; J Parno; K Reich Journal: J Eur Acad Dermatol Venereol Date: 2019-09-11 Impact factor: 6.166
Authors: Eleni Kampylafka; Koray Tascilar; Veronika Lerchen; Christina Linz; Maria Sokolova; Ana Zekovic; Arnd Kleyer; David Simon; Jürgen Rech; Michael Sticherling; Georg Schett; Axel J Hueber Journal: Arthritis Res Ther Date: 2020-09-09 Impact factor: 5.156
Authors: Mark G Lebwohl; Andrew Blauvelt; Alan Menter; Kim A Papp; Scott Guenthner; Radhakrishnan Pillai; Robert J Israel; Abby Jacobson Journal: Am J Clin Dermatol Date: 2019-12 Impact factor: 7.403